FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation.

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Science

Share FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

Sign up to save your podcasts

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer